Clinical trial
Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous…
NCT00081926 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00081926 |
|---|---|
| Title | Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | Gleevec |
| Enrollment | 112 |
| Start date | Oct 1, 2003 |
| Completion | Mar 1, 2007 |
| First posted | Apr 29, 2004 |
| Last update posted | Nov 23, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: